Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Identify and Report Medication Monitoring Irregularities

Panama City, Florida Survey Completed on 05-22-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that the consultant pharmacist identified and reported irregularities related to the long-term use of anti-psychotic and thyroid medications for one resident. The resident had been receiving Levothyroxine Sodium for hypothyroidism and Abilify for bipolar disorder over an extended period. Review of the medical record showed there were no current physician's orders for laboratory testing to monitor thyroid function (TSH or free T4) or fasting blood glucose, despite the known need for such monitoring with these medications. The last available laboratory data was from a hospital visit, not from routine facility-ordered monitoring, and showed abnormal glucose levels. Over the past year, monthly medication regimen reviews by the consultant pharmacist did not include any recommendations for necessary laboratory assessments related to the use of Levothyroxine Sodium or Abilify. Interviews with the DON and the consultant pharmacist confirmed the absence of such monitoring and recommendations. The facility's policy requires comprehensive monthly medication reviews, including evaluation of medication response and reporting of findings, but this was not followed in this case.

An unhandled error has occurred. Reload 🗙